• 1

    KhoranaAAFrancisCWCulakovaE. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol2006;24:484-490.

  • 2

    SallahSWanJYNguyenNP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost2002;87:575-579.

    • Search Google Scholar
    • Export Citation
  • 3

    Heit JAO'Fallon WMPettersonTM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med2002;162:1245-1248.

    • Search Google Scholar
    • Export Citation
  • 4

    MonrealMFernandez-LlamazaresJPerandreuJ. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost1997;78:1316-1318.

    • Search Google Scholar
    • Export Citation
  • 5

    BickRL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol2006;4:115-120.

  • 6

    LopezJAKearonCLeeAY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program2004:439-456.

  • 7

    PrandoniPPiccioliAGirolamiA. Cancer and venous thromboembolism: an overview. Haematologica1999;84:437-445.

  • 8

    OttenHMMathijssenJten CateH. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med2004;164:190-194.

    • Search Google Scholar
    • Export Citation
  • 9

    ChewHKWunTHarveyD. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med2006;166:458-464.

    • Search Google Scholar
    • Export Citation
  • 10

    ChewHKWunTHarveyDJ. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol2007;25:70-76.

    • Search Google Scholar
    • Export Citation
  • 11

    KudererNMFrancisCWCulakovaE. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 9521.

    • Search Google Scholar
    • Export Citation
  • 12

    MartinoMAWilliamsonESiegfriedS. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol2005;98:289-293.

    • Search Google Scholar
    • Export Citation
  • 13

    SorensenHTMellemkjaerLOlsenJHBaronJA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med2000;343:1846-1850.

  • 14

    AgnelliGBolisGCapussottiL. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg2006;243:89-95.

    • Search Google Scholar
    • Export Citation
  • 15

    KakkarAKLevineMPinedoHM. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist2003;8:381-388.

  • 16

    CohenATTapsonVFBergmannJF. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet2008;371:387-394.

    • Search Google Scholar
    • Export Citation
  • 17

    TapsonVFDecoususHPiniM. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest2007;132:936-945.

    • Search Google Scholar
    • Export Citation
  • 18

    AlikhanRPetersFWilmottRCohenAT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol2004;57:1254-1257.

  • 19

    CohenATAlikhanRArcelusJI. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost2005;94:750-759.

    • Search Google Scholar
    • Export Citation
  • 20

    KhoranaAAConnollyGC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol2009;27:4839-4847.

  • 21

    ConnollyGCKhoranaAA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res2010;125(Suppl 2):1-7.

    • Search Google Scholar
    • Export Citation
  • 22

    AgenoWSquizzatoAGarciaDImbertiD. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost2006;32:651-658.

  • 23

    HicksLKCheungMCDingK. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer2009;115:5516-5525.

    • Search Google Scholar
    • Export Citation
  • 24

    KhoranaAAKudererNMCulakovaE. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood2008;111:4902-4907.

    • Search Google Scholar
    • Export Citation
  • 25

    KhoranaAAFrancisCWCulakovaELymanGH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer2005;104:2822-2829.

    • Search Google Scholar
    • Export Citation
  • 26

    MandalàMBarniSPrinsM. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol2010;21:871-876.

    • Search Google Scholar
    • Export Citation
  • 27

    DarzeESLatadoALGuimaraesAG. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest2005;128:2576-2580.

    • Search Google Scholar
    • Export Citation
  • 28

    KrogerKWeilandDOseC. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol2006;17:297-303.

  • 29

    PrandoniPLensingAWPrinsMH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med2002;137:955-960.

    • Search Google Scholar
    • Export Citation
  • 30

    PrandoniPLensingAWPiccioliA. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100:3484-3488.

    • Search Google Scholar
    • Export Citation
  • 31

    BlomJWDoggenCJMOsantoSRosendaalFR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA2005;293:715-722.

  • 32

    HeitJASilversteinMDMohrDN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med2000;160:809-815.

    • Search Google Scholar
    • Export Citation
  • 33

    OgrenMBergqvistDWahlanderK. Trousseau's syndrome–what is the evidence? A population-based autopsy study. Thromb Haemost2006;95:541-545.

    • Search Google Scholar
    • Export Citation
  • 34

    HallIEAndersenMSKrumholzHMGrossCP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol2009:182521.

    • Search Google Scholar
    • Export Citation
  • 35

    SandhuRPanC-XWunT. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer2010;116:2596-2603.

    • Search Google Scholar
    • Export Citation
  • 36

    LevitanNDowlatiARemickSC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore)1999;78:285-291.

    • Search Google Scholar
    • Export Citation
  • 37

    GerberDEGrossmanSAStreiffMB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol2006;24:1310-1318.

    • Search Google Scholar
    • Export Citation
  • 38

    LeeAYLevineMN. Venous thromboembolism and cancer: risks and outcomes. Circulation2003;107:17-21.

  • 39

    MarrasLCGeertsWHPerryJR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer2000;89:640-646.

    • Search Google Scholar
    • Export Citation
  • 40

    FalangaAMarchettiM. Venous thromboembolism in the hematologic malignancies. J Clin Oncol2009;27:4848-4857.

  • 41

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414-423.

  • 42

    OttingerHBelkaCKozoleG. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol1995;54:186-194.

    • Search Google Scholar
    • Export Citation
  • 43

    AndtbackaRHIBabieraGSingletarySE. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg2006;243:96-101.

    • Search Google Scholar
    • Export Citation
  • 44

    HaddadTCGreenoEW. Chemotherapy-induced thrombosis. Thromb Res2006;118:555-568.

  • 45

    AyCDunklerDMarosiC. Prediction of venous thromboembolism in cancer patients. Blood2010;116:5377-5382.

  • 46

    CummingsSREckertSKruegerKA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:2189-2197.

    • Search Google Scholar
    • Export Citation
  • 47

    DecensiAMaisonneuvePRotmenszN. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation2005;111:650-656.

    • Search Google Scholar
    • Export Citation
  • 48

    FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:1652-1662.

    • Search Google Scholar
    • Export Citation
  • FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst1998;90:1371-1388.

    • Search Google Scholar
    • Export Citation
  • 50

    VogelVGCostantinoJPWickerhamDL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila)2010;3:696-706.

    • Search Google Scholar
    • Export Citation
  • 51

    AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291:1701-1712.

    • Search Google Scholar
    • Export Citation
  • 52

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321-333.

    • Search Google Scholar
    • Export Citation
  • 53

    Blanco-MolinaATrujillo-SantosJTiradoR. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE registry. Thromb Haemost2009;101:478-482.

    • Search Google Scholar
    • Export Citation
  • 54

    GomesMPDeitcherSR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med2004;164:1965-1976.

    • Search Google Scholar
    • Export Citation
  • 55

    LeafANPropertKCorcoranC. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol2003;20:137-146.

    • Search Google Scholar
    • Export Citation
  • 56

    BennettCLAngelottaCYarnoldPR. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA2006;296:2558-2560.

    • Search Google Scholar
    • Export Citation
  • 57

    El AccaouiRNShamseddeenWATaherAT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost2007;97:1031-1036.

  • 58

    HusseinMA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost2006;95:924-930.

    • Search Google Scholar
    • Export Citation
  • 59

    KnightRDeLapRJZeldisJB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med2006;354:2079-2080.

  • 60

    WeberDMChenCNiesvizkyR. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med2007;357:2133-2142.

    • Search Google Scholar
    • Export Citation
  • 61

    ZangariMSiegelEBarlogieB. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood2002;100:1168-1171.

    • Search Google Scholar
    • Export Citation
  • 62

    NalluriSRChuDKeresztesR. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA2008;300:2277-2285.

    • Search Google Scholar
    • Export Citation
  • 63

    BennettCLSilverSMDjulbegovicB. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299:914-924.

    • Search Google Scholar
    • Export Citation
  • 64

    BaarslagHJKoopmanMMHuttenBA. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med2004;15:503-507.

    • Search Google Scholar
    • Export Citation
  • 65

    PrandoniPPolistenaPBernardiE. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med1997;157:57-62.

    • Search Google Scholar
    • Export Citation
  • 66

    VersoMAgnelliG. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol2003;21:3665-3675.

    • Search Google Scholar
    • Export Citation
  • 67

    LeeAYLevineMNButlerG. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol2006;24:1404-1408.

    • Search Google Scholar
    • Export Citation
  • 68

    JoffeHVGoldhaberSZ. Upper-extremity deep vein thrombosis. Circulation2002;106:1874-1880.

  • 69

    LinenbergerML. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw2006;4:889-901.

  • 70

    van RoodenCJSchippersEFBargeRM. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol2005;23:2655-2660.

    • Search Google Scholar
    • Export Citation
  • 71

    KearonCGinsbergJSDouketisJ. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med2006;144:812-821.

    • Search Google Scholar
    • Export Citation
  • 72

    WellsPSAndersonDRRodgerM. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med2003;349:1227-1235.

  • 73

    SohneMKruipMJNijkeuterM. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost2006;4:1042-1046.

    • Search Google Scholar
    • Export Citation
  • 74

    KnowlsonLBacchuSPaneeshaS. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol2010;63:818-822.

    • Search Google Scholar
    • Export Citation
  • 75

    AgnelliGVersoMAgenoW. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res2008;121:605-610.

  • 76

    ZierlerBK. Ultrasonography and diagnosis of venous thromboembolism. Circulation2004;109:I9-14.

  • 77

    BirdwellBGRaskobGEWhitsettTL. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med1998;128:1-7.

    • Search Google Scholar
    • Export Citation
  • 78

    KanneJPLalaniTA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation2004;109:15-21.

    • Search Google Scholar
    • Export Citation
  • 79

    LimKEHsuWCHsuYY. Deep venous thrombosis: comparison of indirect multidetector CT venography and sonography of lower extremities in 26 patients. Clin Imaging2004;28:439-444.

    • Search Google Scholar
    • Export Citation
  • 80

    MaleCChaitPGinsbergJS. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost2002;87:593-598.

    • Search Google Scholar
    • Export Citation
  • 81

    SegalJBEngJJenckesMW. Diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Evid Rep Technol Assess (Summ)2003:1-6.

    • Search Google Scholar
    • Export Citation
  • 82

    GaitiniD. Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound2006;34:289-297.

    • Search Google Scholar
    • Export Citation
  • 83

    TaffoniMJRavenelJGAckermanSJ. Prospective comparison of indirect CT venography versus venous sonography in ICU patients. AJR Am J Roentgenol2005;185:457-462.

    • Search Google Scholar
    • Export Citation
  • 84

    FraserDGMoodyARDavidsonIR. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology2003;226:812-820.

    • Search Google Scholar
    • Export Citation
  • 85

    SampsonFCGoodacreSWThomasSMvan BeekEJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol2007;17:175-181.

    • Search Google Scholar
    • Export Citation
  • 86

    JoffeHVKucherNTapsonVFGoldhaberSZ. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation2004;110:1605-1611.

    • Search Google Scholar
    • Export Citation
  • 87

    BaarslagHJvan BeekEJKoopmanMMReekersJA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med2002;136:865-872.

    • Search Google Scholar
    • Export Citation
  • 88

    DecoususHQuereIPreslesE. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med2010;152:218-224.

    • Search Google Scholar
    • Export Citation
  • 89

    LeeJTKalaniMA. Treating superficial venous thrombophlebitis. J Natl Compr Canc Netw2008;6:760-765.

  • 90

    SackGHLevinJBellWR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore)1977;56:1-37.

    • Search Google Scholar
    • Export Citation
  • 91

    VarkiA. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood2007;110:1723-1729.

  • 92

    MartinelliIFranchiniMMannucciPM. How I treat rare venous thromboses. Blood2008;112:4818-4823.

  • 93

    ThatipelliMRMcBaneRDHodgeDOWysokinskiWE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol2010;8:200-205.

    • Search Google Scholar
    • Export Citation
  • 94

    AmitranoLGuardascioneMAScaglioneM. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol2007;102:2464-2470.

    • Search Google Scholar
    • Export Citation
  • 95

    JanssenHLWijnhoudAHaagsmaEB. Extrahepatic portal vein thrombosis: etiology and determinants of survival. Gut2001;49:720-724.

  • 96

    AcostaSAlhadadASvenssonPEkbergO. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg2008;95:1245-1251.

    • Search Google Scholar
    • Export Citation
  • 97

    HedayatiNRihaGMKougiasP. Prognostic factors and treatment outcome in mesenteric vein thrombosis. Vasc Endovascular Surg2008;42:217-224.

    • Search Google Scholar
    • Export Citation
  • 98

    De StefanoVMartinelliI. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med2010;5:487-494.

  • 99

    JanssenHLMeinardiJRVleggaarFP. Factor V leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood2000;96:2364-2368.

    • Search Google Scholar
    • Export Citation
  • 100

    KumarSSarrMGKamathPS. Mesenteric venous thrombosis. N Engl J Med2001;345:1683-1688.

  • 101

    ConnollyGCChenRHyrienO. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res2008;122:299-306.

    • Search Google Scholar
    • Export Citation
  • 102

    GretenTFPapendorfFBleckJS. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer2005;92:1862-1868.

    • Search Google Scholar
    • Export Citation
  • 103

    RabeCPilzTKlostermannC. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol2001;7:208-215.

    • Search Google Scholar
    • Export Citation
  • 104

    CabibboGEneaMAttanasioM. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology2010;51:1274-1283.

    • Search Google Scholar
    • Export Citation
  • 105

    HoekstraJJanssenHL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med2008;66:334-339.

    • Search Google Scholar
    • Export Citation
  • 106

    HoekstraJJanssenHL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med2009;67:46-53.

  • 107

    MenonKVShahVKamathPS. The Budd-Chiari syndrome. N Engl J Med2004;350:578-585.

  • 108

    ParikhSShahRKapoorP. Portal vein thrombosis. Am J Med2010;123:111-119.

  • 109

    PlessierADarwish-MuradSHernandez-GuerraM. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology2010;51:210-218.

    • Search Google Scholar
    • Export Citation
  • 110

    SogaardKKAstrupLBVilstrupHGronbaekH. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol2007;7:34.

    • Search Google Scholar
    • Export Citation
  • 111

    BradburyMSKavanaghPVBechtoldRE. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. Radiographics2002;22:527-541.

  • 112

    PonzianiFRZoccoMACampanaleC. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol2010;16:143-155.

    • Search Google Scholar
    • Export Citation
  • 113

    HillmenPLewisSMBesslerM. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med1995;333:1253-1258.

  • 114

    SocieGMaryJYde GramontA. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet1996;348:573-577.

    • Search Google Scholar
    • Export Citation
  • 115

    HoekstraJLeebeekFWPlessierA. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol2009;51:696-706.

    • Search Google Scholar
    • Export Citation
  • 116

    BaxterEJScottLMCampbellPJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet2005;365:1054-1061.

    • Search Google Scholar
    • Export Citation
  • 117

    JamesCUgoVLe CouedicJP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature2005;434:1144-1148.

    • Search Google Scholar
    • Export Citation
  • 118

    KralovicsRPassamontiFBuserAS. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med2005;352:1779-1790.

  • 119

    LevineRLWadleighMCoolsJ. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell2005;7:387-397.

    • Search Google Scholar
    • Export Citation
  • 120

    ColaizzoDAmitranoLTisciaGL. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost2007;5:55-61.

    • Search Google Scholar
    • Export Citation
  • 121

    De StefanoVFioriniARossiE. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost2007;5:708-714.

    • Search Google Scholar
    • Export Citation
  • 122

    ReginaSHeraultOD'AlterocheL. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost2007;5:859-861.

    • Search Google Scholar
    • Export Citation
  • 123

    ColaizzoDAmitranoLTisciaGL. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood2007;110:2768-2769.

    • Search Google Scholar
    • Export Citation
  • 124

    FanikosJGoldhaberSZ. Risk factors for the assessment of patients with pulmonary embolism. J Natl Compr Canc Netw2006;4:871-880.

  • 125

    KearonCGinsbergJSHirshJ. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med1998;129:1044-1049.

    • Search Google Scholar
    • Export Citation
  • 126

    MoserKMFedulloPFLitteJohnJKCrawfordR. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA1994;271:223-225.

    • Search Google Scholar
    • Export Citation
  • 127

    O'ConnellCLBoswellWDDuddalwarV. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol2006;24:4928-4932.

    • Search Google Scholar
    • Export Citation
  • 128

    WorsleyDFAlaviAAronchickJM. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. Radiology1993;189:133-136.

    • Search Google Scholar
    • Export Citation
  • 129

    CostantiniMBossoneERennaR. Electrocardiographic features in critical pulmonary embolism. Results from baseline and continuous electrocardiographic monitoring. Ital Heart J2004;5:214-216.

    • Search Google Scholar
    • Export Citation
  • 130

    FerrariEImbertAChevalierT. The ECG in pulmonary embolism. Predictive value of negative T waves in precordial leads–80 case reports. Chest1997;111:537-543.

    • Search Google Scholar
    • Export Citation
  • 131

    SchoepfUJCostelloP. CT angiography for diagnosis of pulmonary embolism: state of the art. Radiology2004;230:329-337.

  • 132

    Czekajska-ChehabEDropATerleckaB. Indirect CT venography of the abdominal cavity and lower limbs in patients with the suspicion of pulmonary embolism–indications, technique, diagnostic possibilities. Ann Univ Mariae Curie Sklodowska Med2004;59:508-518.

    • Search Google Scholar
    • Export Citation
  • 133

    SchoepfUJKucherNKipfmuellerF. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation2004;110:3276-3280.

    • Search Google Scholar
    • Export Citation
  • 134

    AndersonDRKahnSRRodgerMA. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA2007;298:2743-2753.

    • Search Google Scholar
    • Export Citation
  • 135

    Calvo-RomeroJMLima-RodriguezEMBureo-DacalPPerez-MirandaM. Predictors of an intermediate ventilation/perfusion lung scan in patients with suspected acute pulmonary embolism. Eur J Emerg Med2005;12:129-131.

    • Search Google Scholar
    • Export Citation
  • 136

    GoldhaberSZVisaniLDe RosaM. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet1999;353:1386-1389.

    • Search Google Scholar
    • Export Citation
  • 137

    JimenezDAujeskyDMooresL. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax2011;66:75-81.

    • Search Google Scholar
    • Export Citation
  • 138

    JimenezDAujeskyDYusenRD. Risk stratification of normotensive patients with acute symptomatic pulmonary embolism. Br J Haematol2010;151:415-424.

    • Search Google Scholar
    • Export Citation
  • 139

    KucherNGoldhaberSZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation2003;108:2191-2194.

    • Search Google Scholar
    • Export Citation
  • 140

    KucherNGoldhaberSZ. Management of massive pulmonary embolism. Circulation2005;112:e28-32.

  • 141

    PruszczykPTorbickiAKuch-WocialA. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart2001;85:628-634.

    • Search Google Scholar
    • Export Citation
  • 142

    RibeiroALindmarkerPJuhlin-DannfeltA. Echocardiography doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J1997;134:479-487.

    • Search Google Scholar
    • Export Citation
  • 143

    BecattiniCVedovatiMCAgnelliG. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation2007;116:427-433.

  • 144

    KonstantinidesSGeibelAOlschewskiM. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation2002;106:1263-1268.

    • Search Google Scholar
    • Export Citation
  • 145

    JimenezDAujeskyDDiazG. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med2010;181:983-991.

    • Search Google Scholar
    • Export Citation
  • 146

    AujeskyDRoyPMLe ManachCP. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J2006;27:476-481.

    • Search Google Scholar
    • Export Citation
  • 147

    DonzeJLe GalGFineMJ. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost2008;100:943-948.

    • Search Google Scholar
    • Export Citation
  • 148

    LEO Pharmaceutical Products. Prescribing information: Innohep (tinzaparin sodium injection) for subcutaneous (SC) use only. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020484s011lbl.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 149

    sanofi-aventis U.S. LLC. Prescribing information: Lovenox (enoxaparin sodium injection). 2009. Available at: http://products.sanofi-aventis.us/lovenox/lovenox.html. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 150

    GlaxoSmithKline. Prescribing information: ARIXTRA (fondaparinux sodium) Solution for subcutaneous injection. 2010. Available at: http://us.gsk.com/products/assets/us_arixtra.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 151

    Eisai Inc; Pfizer Inc.Prescribing information: FRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf. Accessed March 2 2011.

    • Search Google Scholar
    • Export Citation
  • 152

    Hospira Inc.Prescribing information: Heparin sodium injection USP. 2008. Available at: http://www.hospira.com/Files/heparin_sodium_injection.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 153

    CerveraRKhamashtaMAShoenfeldY. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis2009;68:1428-1432.

    • Search Google Scholar
    • Export Citation
  • 154

    LimWCrowtherMAEikelboomJW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA2006;295:1050-1057.

  • 155

    LimW. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program2009:233-239.

  • 156

    HuttenBAPrinsMHGentM. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol2000;18:3078-3083.

    • Search Google Scholar
    • Export Citation
  • 157

    PalaretiGLegnaniCLeeA. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost2000;84:805-810.

    • Search Google Scholar
    • Export Citation
  • 158

    HullRDPineoGFBrantRF. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med2006;119:1062-1072.

    • Search Google Scholar
    • Export Citation
  • 159

    LeeAYLevineMNBakerRI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med2003;349:146-153.

    • Search Google Scholar
    • Export Citation
  • 160

    MeyerGMarjanovicZValckeJ. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med2002;162:1729-1735.

    • Search Google Scholar
    • Export Citation
  • 161

    WawrzynskaLTomkowskiWZPrzedlackiJ. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb2003;33:64-67.

    • Search Google Scholar
    • Export Citation
  • 162

    AronsonJ. Serious drug interactions. Practitioner1993;237:789-791.

  • 163

    LaceyCS. Interaction of dicloxacillin with warfarin. Ann Pharmacother2004;38:898.

  • 164

    SaifMW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer2005;5:175-180.

  • 165

    ShahHRLedbetterLDiasioRSaifMW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer2006;5:354-358.

    • Search Google Scholar
    • Export Citation
  • 166

    MorelloKCWurzGTDeGregorioMW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet2003;42:361-372.

  • 167

    NutescuEAShapiroNLIbrahimSWestP. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf2006;5:433-451.

    • Search Google Scholar
    • Export Citation
  • 168

    SconceEKhanTMasonJ. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost2005;93:872-875.

    • Search Google Scholar
    • Export Citation
  • 169

    WittkowskyAKBoccuzziSJWogenJ. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy2004;24:1668-1674.

    • Search Google Scholar
    • Export Citation
  • 170

    BarrittDWJordanSC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet1960;1:1309-1312.

  • 171

    HirshJBatesSM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med2001;134:409-417.

    • Search Google Scholar
    • Export Citation
  • 172

    GeertsWHBergqvistDPineoGF. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(Suppl 6):381S-453S.

    • Search Google Scholar
    • Export Citation
  • 173

    KearonCKahnSRAgnelliG. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(Suppl 6):454S-545S.

    • Search Google Scholar
    • Export Citation
  • 174

    WellsPSAndersonDRRodgerMA. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med2005;165:733-738.

    • Search Google Scholar
    • Export Citation
  • 175

    CheerSMDunnCJFosterR. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs2004;64:1479-1502.

    • Search Google Scholar
    • Export Citation
  • 176

    NeelyJLCarlsonSSLenhartSE. Tinzaparin sodium: a low-molecular-weight heparin. Am J Health Syst Pharm2002;59:1426-1436.

  • 177

    NutescuEAShapiroNLFeinsteinHRiversCW. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother2003;37:1831-1840.

  • 178

    PlanesASamamaMMLensingAW. Prevention of deep vein thrombosis after hip replacement–comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost1999;81:22-25.

    • Search Google Scholar
    • Export Citation
  • 179

    MandalàMFalangaARoilaF. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol2008;19(Suppl 2):126-127.

    • Search Google Scholar
    • Export Citation
  • 180

    CookLMKahnSRGoodwinJKovacsMJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost2007;5:937-941.

    • Search Google Scholar
    • Export Citation
  • 181

    HirshJBauerKADonatiMB. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(Suppl 6):141S-159S.

    • Search Google Scholar
    • Export Citation
  • 182

    MichotaFMerliG. Anticoagulation in special patient populations: are special dosing considerations required?Cleve Clin J Med2005;72(Suppl 1):S37-42.

    • Search Google Scholar
    • Export Citation
  • 183

    SanderinkGJGuimartCGOzouxML. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res2002;105:225-231.

    • Search Google Scholar
    • Export Citation
  • 184

    LimWDentaliFEikelboomJWCrowtherMA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med2006;144:673-684.

    • Search Google Scholar
    • Export Citation
  • 185

    HulotJSMontalescotGLechatP. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther2005;77:542-552.

    • Search Google Scholar
    • Export Citation
  • 186

    KruseMWLeeJJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J2004;148:582-589.

    • Search Google Scholar
    • Export Citation
  • 187

    ShprecherARCheng-LaiAMadsenEM. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy2005;25:817-822.

    • Search Google Scholar
    • Export Citation
  • 188

    DouketisJCookDMeadeM. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med2008;168:1805-1812.

    • Search Google Scholar
    • Export Citation
  • 189

    MaheIAghassarianMDrouetL. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost2007;97:581-586.

    • Search Google Scholar
    • Export Citation
  • 190

    PautasEGouinIBellotO. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf2002;25:725-733.

    • Search Google Scholar
    • Export Citation
  • 191

    SiguretVPautasEFevrierM. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost2000;84:800-804.

    • Search Google Scholar
    • Export Citation
  • 192

    LeizoroviczA. Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency–the IRIS trial [abstract]. Blood2008;112:Abstract 434.

    • Search Google Scholar
    • Export Citation
  • 193

    KucherNLeizoroviczAVaitkusPT. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med2005;165:341-345.

    • Search Google Scholar
    • Export Citation
  • 194

    PrandoniP. How I treat venous thromboembolism in patients with cancer. Blood2005;106:4027-4033.

  • 195

    SaviPChongBHGreinacherA. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood2005;105:139-144.

    • Search Google Scholar
    • Export Citation
  • 196

    WarkentinTEGreinacherAKosterALincoffAM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest2008;133(Suppl 6):340S-380S.

    • Search Google Scholar
    • Export Citation
  • 197

    CohenATDavidsonBLGallusAS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ2006;332:325-329.

    • Search Google Scholar
    • Export Citation
  • 198

    HirshJAnandSSHalperinJLFusterV. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol2001;21:1094-1096.

    • Search Google Scholar
    • Export Citation
  • 199

    ClagettGPReischJS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg1988;208:227-240.

    • Search Google Scholar
    • Export Citation
  • 200

    KingCSHolleyABJacksonJL. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest2007;131:507-516.

    • Search Google Scholar
    • Export Citation
  • 201

    KearonCGinsbergJSJulianJA. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA2006;296:935-942.

    • Search Google Scholar
    • Export Citation
  • 202

    Bristol-Myers Squibb. Prescribing information: COUMADIN® TABLETS (Warfarin Sodium Tablets USP); COUMADIN® FOR INJECTION (Warfarin Sodium for Injection USP). 2010. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 203

    GlynnRJRidkerPMGoldhaberSZBuringJE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med2007;147:525-533.

    • Search Google Scholar
    • Export Citation
  • 204

    Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation2005;112:416-422.

    • Search Google Scholar
    • Export Citation
  • 205

    BrenderE. Use of emboli-blocking filters increases, but rigorous data are lacking. JAMA2006;295:989-990.

  • 206

    SteinPDKayaliFOlsonRE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med2004;164:1541-1545.

  • 207

    StreiffMB. Vena caval filters: a comprehensive review. Blood2000;95:3669-3677.

  • 208

    StreiffMB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med2003;18:59-79.

  • 209

    DecoususHLeizoroviczAParentF. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med1998;338:409-415.

    • Search Google Scholar
    • Export Citation
  • 210

    EltingLSEscalanteCPCooksleyC. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med2004;164:1653-1661.

    • Search Google Scholar
    • Export Citation
  • 211

    GetzenTMRectenwaldJE. Inferior vena cava filters in the cancer patient: current use and indications. J Natl Compr Canc Netw2006;4:881-888.

    • Search Google Scholar
    • Export Citation
  • 212

    MillwardSFGrassiCJKinneyTB. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. J Vasc Interv Radiol2005;16:441-443.

    • Search Google Scholar
    • Export Citation
  • 213

    KimHSYoungMJNarayanAK. A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol2008;19:393-399.

    • Search Google Scholar
    • Export Citation
  • 214

    NicholsonWNicholsonWJTolericoP. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med2010;170:1827-1831.

    • Search Google Scholar
    • Export Citation
  • 215

    FrancisCW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol2009;27:4874-4880.

  • 216

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg1997;84:1099-1103.

    • Search Google Scholar
    • Export Citation
  • 217

    MismettiPLaporteSDarmonJY. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg2001;88:913-930.

    • Search Google Scholar
    • Export Citation
  • 218

    DeBernardoRLPerkinsRBLittellRD. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol2005;105:1006-1011.

    • Search Google Scholar
    • Export Citation
  • 219

    AklEATerrenatoIBarbaM. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med2008;168:1261-1269.

    • Search Google Scholar
    • Export Citation
  • 220

    CoubanSGoodyearMBurnellM. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol2005;23:4063-4069.

    • Search Google Scholar
    • Export Citation
  • 221

    KarthausMKretzschmarAKroningH. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol2006;17:289-296.

    • Search Google Scholar
    • Export Citation
  • 222

    VersoMAgnelliGBertoglioS. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol2005;23:4057-4062.

    • Search Google Scholar
    • Export Citation
  • 223

    YoungAMBillinghamLJBegumG. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet2009;373:567-574.

    • Search Google Scholar
    • Export Citation
  • 224

    MartinoMABorgesEWilliamsonE. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol2006;107:666-671.

  • 225

    BergqvistDAgnelliGCohenAT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med2002;346:975-980.

    • Search Google Scholar
    • Export Citation
  • 226

    RasmussenMSJorgensenLNWille-JorgensenP. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost2006;4:2384-2390.

    • Search Google Scholar
    • Export Citation
  • 227

    RanaPLevineMN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol2009;27:4885-4888.

  • 228

    ZangariMFinkLMEliceF. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol2009;27:4865-4873.

  • 229

    Celgene Corporation. Prescribing information: REVLIMID (lenalidomide) capsules. 2010. Available at: http://www.revlimid.com/pdf/REVLIMID_PI.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 230

    Celgene Corporation. Prescribing information: THALOMID® (thalidomide) Capsules 50 mg 100 mg 150 mg & 200 mg. 2010. Available at: http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf. Accessed February 18 2011.

    • Search Google Scholar
    • Export Citation
  • 231

    PalumboACavoMBringhenS. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide:a phase III, open-label, randomized trial. J Clin Oncol2011;29:986-993.

    • Search Google Scholar
    • Export Citation
  • 232

    AgnelliGGussoniGBianchiniC. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol2009;10:943-949.

    • Search Google Scholar
    • Export Citation
  • 233

    RiessHPelzerUOpitzB. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract 4033.

    • Search Google Scholar
    • Export Citation
  • 234

    CohenATNandiniBWillsJOOtaS. VTE prophylaxis for the medical patient: where do we stand?–a focus on cancer patients. Thromb Res2010;125(Suppl 2):S21-29.

    • Search Google Scholar
    • Export Citation
  • 235

    Clarke-PearsonDLSynanISDodgeR. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol1993;168:1146-1153.

    • Search Google Scholar
    • Export Citation
  • 236

    RamirezJIVassiliuPGonzalez-RuizC. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg2003;69:941-945.

    • Search Google Scholar
    • Export Citation
  • 237

    AmaragiriSVLeesTA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev2000;3:CD001484.

  • 238

    CohenATSkinnerJAWarwickDBrenkelI. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br2007;89:887-892.

    • Search Google Scholar
    • Export Citation
  • 239

    DennisMSandercockPAReidJ. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet2009;373:1958-1965.

    • Search Google Scholar
    • Export Citation
  • 240

    JaffMRMcMurtryMSArcherSL. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation2011;123:1788-1830.

    • Search Google Scholar
    • Export Citation
  • 241

    ComerotaAJAldridgeSC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg1993;36:359-364.

  • 242

    MewissenMWSeabrookGRMeissnerMH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology1999;211:39-49.

    • Search Google Scholar
    • Export Citation
  • 243

    EndenTKlowNESandvikL. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost2009;7:1268-1275.

    • Search Google Scholar
    • Export Citation
  • 244

    KimHSPreeceSRBlackJH. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg2008;47:388-394.

    • Search Google Scholar
    • Export Citation
  • 245

    DolovichLRGinsbergJSDouketisJD. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med2000;160:181-188.

    • Search Google Scholar
    • Export Citation
  • 246

    BullerHRDavidsonBLDecoususH. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med2003;349:1695-1702.

    • Search Google Scholar
    • Export Citation
  • 247

    AklEAVasireddiSRGunukulaS. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev2011;2:CD006649.

    • Search Google Scholar
    • Export Citation
  • 248

    DeitcherSRKesslerCMMerliG. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost2006;12:389-396.

    • Search Google Scholar
    • Export Citation
  • 249

    HullRDPineoGFMahAF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. J Thromb Haemost2003;1(Suppl 1):Abstract OC395.

    • Search Google Scholar
    • Export Citation
  • 250

    AklEABarbaMRohillaS. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev2008;2:CD006650.

    • Search Google Scholar
    • Export Citation
  • 251

    KakkarAKLevineMNKadziolaZ. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol2004;22:1944-1948.

    • Search Google Scholar
    • Export Citation
  • 252

    LeeAYRicklesFRJulianJA. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol2005;23:2123-2129.

    • Search Google Scholar
    • Export Citation
  • 253

    AltinbasMCoskunHSErO. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost2004;2:1266-1271.

    • Search Google Scholar
    • Export Citation
  • 254

    KlerkCPSmorenburgSMOttenHM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol2005;23:2130-2135.

    • Search Google Scholar
    • Export Citation
  • 255

    AklEAvan DoormaalFFBarbaM. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res2008;27:4.

    • Search Google Scholar
    • Export Citation
  • 256

    KovacsMJKahnSRRodgerM. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost2007;5:1650-1653.

    • Search Google Scholar
    • Export Citation
  • 257

    LeonLGiannoukasADDoddD. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg2005;29:10-17.

  • 258

    van WeertHDolanGWichersI. Spontaneous superficial venous thrombophlebitis: does it increase risk for thromboembolism? A historic follow-up study in primary care. J Fam Pract2006;55:52-57.

    • Search Google Scholar
    • Export Citation
  • 259

    MarchioriAVerlatoFSabbionP. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica2002;87:523-527.

    • Search Google Scholar
    • Export Citation
  • 260

    A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med2003;163:1657-1663.

    • Search Google Scholar
    • Export Citation
  • 261

    CondatBPessioneFHillaireS. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology2001;120:490-497.

    • Search Google Scholar
    • Export Citation
  • 262

    DentaliFAgenoWWittD. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost2009;102:501-504.

    • Search Google Scholar
    • Export Citation
  • 263

    HollingsheadMBurkeCTMauroMA. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol2005;16:651-661.

    • Search Google Scholar
    • Export Citation
  • 264

    KimHSPatraAKhanJ. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol2005;16:1685-1691.

    • Search Google Scholar
    • Export Citation
  • 265

    SharmaSTexeiraATexeiraP. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol2004;40:172-180.

    • Search Google Scholar
    • Export Citation
  • 266

    SmalbergJHSpaanderMVJieKS. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost2008;100:1084-1088.

    • Search Google Scholar
    • Export Citation
  • 267

    Garcia-PaganJCHeydtmannMRaffaS. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology2008;135:808-815.

    • Search Google Scholar
    • Export Citation
  • 268

    Darwish MuradSPlessierAHernandez-GuerraM. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med2009;151:167-175.

    • Search Google Scholar
    • Export Citation
  • 269

    EapenCEVelissarisDHeydtmannM. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut2006;55:878-884.

    • Search Google Scholar
    • Export Citation
  • 270

    MancusoAFungKMelaM. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol2003;38:751-754.

  • 271

    PerelloAGarcia-PaganJCGilabertR. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology2002;35:132-139.

    • Search Google Scholar
    • Export Citation
  • 272

    RossleMOlschewskiMSiegerstetterV. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery2004;135:394-403.

    • Search Google Scholar
    • Export Citation
  • 273

    HemmingAWLangerBGreigP. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg1996;171:176-180.

    • Search Google Scholar
    • Export Citation
  • 274

    ZeitounGEscolanoSHadengueA. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology1999;30:84-89.

    • Search Google Scholar
    • Export Citation
  • 275

    PanisYBelghitiJVallaD. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery1994;115:276-281.

    • Search Google Scholar
    • Export Citation
  • 276

    Pisani-CerettiAIntraMPrestipinoF. Surgical and radiologic treatment of primary Budd-Chiari syndrome. World J Surg1998;22:48-53.

  • 277

    SlakeyDPKleinASVenbruxACCameronJL. Budd-Chiari syndrome: current management options. Ann Surg2001;233:522-527.

  • 278

    Darwish MuradSVallaDCde GroenPC. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology2004;39:500-508.

    • Search Google Scholar
    • Export Citation
  • 279

    Perez-AyusoRMValderramaSEspinozaM. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol2010;9:15-22.

    • Search Google Scholar
    • Export Citation
  • 280

    LayCSTsaiYTLeeFY. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol2006;21:413-419.

    • Search Google Scholar
    • Export Citation
  • 281

    SchepkeMKleberGNurnbergD. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology2004;40:65-72.

    • Search Google Scholar
    • Export Citation
  • 282

    PsilopoulosDGalanisPGoulasS. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol2005;17:1111-1117.

    • Search Google Scholar
    • Export Citation
  • 283

    SarinSKWadhawanMAgarwalSR. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol2005;100:797-804.

    • Search Google Scholar
    • Export Citation
  • 284

    SarinSKGuptaNJhaSK. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology2010;139:1238-1245.

    • Search Google Scholar
    • Export Citation
  • 285

    FunakoshiNSegalas-LargeyFDunyY. Benefit of combination beta-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol2010;16:5982-5992.

    • Search Google Scholar
    • Export Citation
  • 286

    GoldhaberSZ. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro. Arch Intern Med2005;165:2197-2199.

    • Search Google Scholar
    • Export Citation
  • 287

    ThabutGThabutDMyersRP. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol2002;40:1660-1667.

  • 288

    AgnelliGBecattiniCKirschsteinT. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med2002;162:2537-2541.

    • Search Google Scholar
    • Export Citation
  • 289

    WanSQuinlanDJAgnelliGEikelboomJW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation2004;110:744-749.

    • Search Google Scholar
    • Export Citation
  • 290

    KonstantinidesSGeibelAHeuselG. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med2002;347:1143-1150.

    • Search Google Scholar
    • Export Citation
  • 291

    AshtonRWDanielsCERyuJH. Thrombolytic therapy in patients with submassive pulmonary embolism. N Engl J Med2003;348:357-359; author reply 357-359.

    • Search Google Scholar
    • Export Citation
  • 292

    ThabutGLogeartD. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con. Arch Intern Med2005;165:2200-2203.

    • Search Google Scholar
    • Export Citation
  • 293

    AklogLWilliamsCSByrneJGGoldhaberSZ. Acute pulmonary embolectomy: a contemporary approach. Circulation2002;105:1416-1419.

  • 294

    LeaccheMUnicDGoldhaberSZ. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg2005;129:1018-1023.

    • Search Google Scholar
    • Export Citation
  • 295

    ThistlethwaitePAKempADuL. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg2006;131:307-313.

    • Search Google Scholar
    • Export Citation
  • 296

    BatesSMWeitzJI. Coagulation assays. Circulation2005;112:53-60.

  • 297

    BatesSMWeitzJIJohnstonM. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med2001;161:385-391.

    • Search Google Scholar
    • Export Citation
  • 298

    RaschkeRHirshJGuidryJR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med2003;138:720-723.

    • Search Google Scholar
    • Export Citation
  • 299

    How to validate heparin sensitivity of the aPPT. College of American Pathologists, CAP Today; 2004. Available at: http://www.cap.org. Accessed February 11 2011.

    • Search Google Scholar
    • Export Citation
  • 300

    EichlerPFriesenHJLubenowN. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood2000;96:2373-2378.

    • Search Google Scholar
    • Export Citation
  • 301

    FischerKGLiebeVHudekR. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost2003;89:973-982.

    • Search Google Scholar
    • Export Citation
  • 302

    SongXHuhleGWangL. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation1999;100:1528-1532.

    • Search Google Scholar
    • Export Citation
  • 303

    GreinacherALubenowNEichlerP. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation2003;108:2062-2065.

    • Search Google Scholar
    • Export Citation
  • 304

    EichlerPLubenowNStrobelUGreinacherA. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood2004;103:613-616.

    • Search Google Scholar